ArticlePorcine health management2025
Efficacy and safety of intradermal vaccination against porcine circovirus type 2 and Mycoplasma hyopneumoniae under combined exposure field conditions.
Article in Porcine health management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety and reproductive performance in sows after vaccination: a randomized controlled trial.Veterinary research communications · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPorcine circovirus 2 (PCV2) and Mycoplasma hyopneumoniae (M hyo) are two of the most important swine pathogens with variable clinical presence in swine farms globally, affecting health and performance of pigs under field conditions. The primary objective of this study was to assess the efficacy of a ready to use intradermal (ID) vaccine (Porcilis PCV M Hyo ID, MSD Animal Health, The Netherlands) against PCV2 associated disease and M hyo associated enzootic pneumonia under practical (field) conditions. In addition, the safety of the test product was clinically assessed, as the study animals were examined for general and local side effects after vaccination. A total of 678 animals in a Greek farrow to finish farm were equally divided in two trial groups (test and control group). Test group animals received the test vaccine at the age of three weeks, while control group animals remained unvaccinated. Parameters regarding health [lung lesion score (LLS) and pleurisy scoring, PCV2 viraemia and shedding] and performance [body weight (BW), average daily weight gain (ADWG)] were recorded and evaluated.
resultsVaccination improved the ADWG during both the finishing period (improvement by 34 g; p < 0.0001), and the overall period (increase by 24 g; p < 0.0001). Moreover, reduced mean LLS values (p < 0.0001), as well as reduced percentage of animals with pleurisy (p = 0.0082) and a decrease in PCV2 viraemia (p < 0.0001) and viral shedding (p = 0.0181) were observed in vaccinated animals when compared with the unvaccinated controls. As regards safety, a slight local skin reaction at the site of vaccination was detected and in two pigs a mild systemic reaction was reported with full recovery.
conclusionsFindings suggested that the test vaccine is safe and effective against both PCV2 and M hyo associated diseases in vivo, thus it's use as part of a vaccination programme under field conditions is expected to improve respective health and performance parameters in pigs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.